To induce OIR, mouse pups are reared in a hyperoxic chamber (P7‐P12, 75% O2), which mimics oxygen exposure in preterm infants in neonatal intensive care.[7, 13] Thus, the OIR model has been widely used to study ROP and develop therapeutic interventions,[13a] suggesting that TRAP1 inhibitors could be used to develop therapeutics for ROP acting via novel mechanisms. The gene discussed is TRAP1; the disease is retinopathy of prematurity.